{"url_path":"/sec/vyne/8-k/2026-07-21/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-21","source_url":"https://www.sec.gov/Archives/edgar/data/1566044/0001104659-26-085235-index.html","accession_number":"0001104659-26-085235","cik":"0001566044","ticker":"VYNE","issuer_name":"Yarrow Bioscience, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1566044/0001104659-26-085235-index.html","primary_entity_key":"0001566044","primary_entity_name":"VYNE Therapeutics Inc."},"word_count":145,"has_tables":true,"body_markdown":"**Item 7.01 Regulation FD Disclosure.**\n\n \n\nOn July 21, 2026, VYNE issued a press release titled “VYNE\nTherapeutics Announces 1-for-50 Reverse Stock Split and Provides Update Regarding Special Dividend in Connection with the Proposed Merger\nwith Yarrow Bioscience.” A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.\n\n \n\nThe information under Item 7.01 of this Current\nReport on Form 8-K (including Exhibit 99.1) is intended to be furnished and shall not be deemed “filed” for purposes\nof Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities\nof that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities\nAct”), or the Exchange Act, except as expressly set forth by specific reference in such filing."}